Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NAAA | Q02083 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10961330 | 0.94 | HPGD (0.88) | HPGDTSHRHTTPOLBNPC1 | |
| SCHEMBL8207967 | 0.94 | HPGD (0.88) | HPGDTSHRHTTPOLBNPC1 | |
| SCHEMBL10792384 | 0.90 | HPGD (0.81) | HPGDTSHRHTTPOLBNPC1 | |
| SCHEMBL9492505 | 0.88 | HPGD (0.78) | HPGDTSHRHTTPOLBNPC1 | |
| SCHEMBL9492258 | 0.88 | HPGD (0.78) | HPGDTSHRHTTPOLBNPC1 | |
| SCHEMBL19210845 | 0.88 | TSHR (1.00) | HPGDTSHRHTTNAAAL3MBTL1 | |
| SCHEMBL28994976 | 0.84 | HPGD (0.73) | HPGDTSHRHTTPOLBNPC1 | |
| SCHEMBL10447428 | 0.84 | HPGD (0.72) | HPGDTSHRHTTPOLBLMNA | |
| SCHEMBL3478151 | 0.83 | HPGD (0.71) | HPGDTSHRHTTPOLBNPC1 | |
| SCHEMBL4148749 | 0.82 | HPGD (0.70) | HPGDPOLBNPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2989083-A1 | PROCESS FOR PREPARING 1,2-BENZISOTHIAZOLIN-3-ONES | Titan Chemicals Limited (VG) | 2016-03-02 | — | — | EP | disclosed |
| US-9067899-B2 | Process for preparing 1,2-benzoisothiazolin-3-ones | TITAN CHEMICALS LIMITED (VG) | 2015-06-30 | — | — | US | disclosed |
| WO-2014173716-A1 | PROCESS FOR PREPARING 1,2-BENZISOTHIAZOLIN-3-ONES | TITAN CHEMICALS LIMITED (VG) | 2014-10-30 | — | — | WO | disclosed |
| US-20140316141-A1 | PROCESS FOR PREPARING 1,2-BENZOISOTHIAZOLIN-3-ONES | TITAN CHEMICALS LIMITED (VG) | 2014-10-23 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| CN-1067215-C | Composition of mouse expelling agent containing amide | SHENYANG CHEMICAL INST MINISTR (CN) | 2001-06-20 | — | — | CN | disclosed |
| US-5003106-A | Antiatherosclerotic ureas and thioureas | AMERICAN CYANAMID COMPANY (US) | 1991-03-26 | — | — | US | disclosed |
| US-4623662-A | ANTICHOLESTEROL, ANTILIPEMIC | AMERICAN CYANAMID COMPANY (US) | 1986-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | HPGD 2359/4885TSHR 184/4885HTT 4255/4885 |
| US-20140316141-A1 | PROCESS FOR PREPARING 1,2-BENZOISOTHIAZOLIN-3-ONES | MPST, CBS, NISCH | HPGD 217/4885TSHR 4019/4885HTT 533/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | HPGD 2359/4885TSHR 184/4885HTT 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.